ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Bayer AG (PK)

Bayer AG (PK) (BAYZF)

21.32
0.00
(0.00%)
Closed 16 January 8:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
21.32
Bid
21.32
Offer
21.32
Volume
-
0.00 Day's Range 0.00
19.50 52 Week Range 36.54
Market Cap
Previous Close
21.32
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
21,777
Shares Outstanding
982,424,082
Dividend Yield
0.50%
PE Ratio
-6.94
Earnings Per Share (EPS)
-2.99
Revenue
47.64B
Net Profit
-2.94B

About Bayer AG (PK)

Sector
Chems, Allied Pds-whsl, Nec
Industry
Chemicals & Allied Products
Website
Headquarters
Leverkusen, Deu
Founded
1998
Bayer AG (PK) is listed in the Chems, Allied Pds-whsl sector of the OTCMarkets with ticker BAYZF. The last closing price for Bayer (PK) was US$21.32. Over the last year, Bayer (PK) shares have traded in a share price range of US$ 19.50 to US$ 36.54.

Bayer (PK) currently has 982,424,082 shares in issue. The market capitalisation of Bayer (PK) is US$20.95 billion. Bayer (PK) has a price to earnings ratio (PE ratio) of -6.94.

BAYZF Latest News

New Adult Hemophilia Quality of Life Tool Now Available for Hemophilia Community

New Adult Hemophilia Quality of Life Tool Now Available for Hemophilia Community Multinational Validation Study of Haemo-Qol-A Presented at WFH Congress RESEARCH TRIANGLE PARK, N.C., Oct. 20...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.542.5986525505320.7821.4320.21054920.90880389CS
41.768.9979550102219.5621.4319.51877820.11941729CS
12-6.8-24.182076813728.1228.15519.52177721.49413725CS
26-6.7941-24.166165731828.114134.013819.51438323.40918432CS
52-14.86-41.072415699336.1836.5419.52088528.298787CS
156-38.7109-64.484956913960.030974.3419.52205846.55818185CS
260-61.23-74.173228346582.5586.3519.51646649.75390194CS

BAYZF - Frequently Asked Questions (FAQ)

What is the current Bayer (PK) share price?
The current share price of Bayer (PK) is US$ 21.32
How many Bayer (PK) shares are in issue?
Bayer (PK) has 982,424,082 shares in issue
What is the market cap of Bayer (PK)?
The market capitalisation of Bayer (PK) is USD 20.95B
What is the 1 year trading range for Bayer (PK) share price?
Bayer (PK) has traded in the range of US$ 19.50 to US$ 36.54 during the past year
What is the PE ratio of Bayer (PK)?
The price to earnings ratio of Bayer (PK) is -6.94
What is the cash to sales ratio of Bayer (PK)?
The cash to sales ratio of Bayer (PK) is 0.43
What is the reporting currency for Bayer (PK)?
Bayer (PK) reports financial results in EUR
What is the latest annual turnover for Bayer (PK)?
The latest annual turnover of Bayer (PK) is EUR 47.64B
What is the latest annual profit for Bayer (PK)?
The latest annual profit of Bayer (PK) is EUR -2.94B
What is the registered address of Bayer (PK)?
The registered address for Bayer (PK) is KAISER-WILHELM-ALLEE 1, LEVERKUSEN, 51368
What is the Bayer (PK) website address?
The website address for Bayer (PK) is www.bayer.com
Which industry sector does Bayer (PK) operate in?
Bayer (PK) operates in the CHEMICALS & ALLIED PRODUCTS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AABVFAberdeen International Inc (PK)
US$ 0.0242
(0.00%)
0
AABKFAareal Bank AG (PK)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0299
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.0242
(0.00%)
0
AABKFAareal Bank AG (PK)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0299
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0
AABVFAberdeen International Inc (PK)
US$ 0.0242
(0.00%)
0
AABKFAareal Bank AG (PK)
US$ 0.00
(0.00%)
0
AABBAsia Broadband Inc (PK)
US$ 0.0299
(0.00%)
0
AAALYAareal Bank AG (PK)
US$ 34.65
(0.00%)
0
AAAIFAlternative Investment Trust (PK)
US$ 0.55
(0.00%)
0

BAYZF Discussion

View Posts
Pastortec Pastortec 9 months ago
BAYER i recommend buy VOIS. The company that sell the stocks sell with them all its patents and one of them can influence with certain on your future sales.
πŸ‘οΈ0
mm41 mm41 10 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 10 months ago
Negative News without end. The stock price is falling like a rock as frustrated investors dump their stocks from their portfolios. Does that even make sense?
I would say NO. The company will certainly survive the crisis because it has had proven and real products for 100 years.
Well, now experts and analysts are making the rounds, and other Internet influencers are also propagating the last rites. So I'm buying. ISIN: DE000BAY0017 | WKN: BAY001
πŸ‘οΈ0
mm41 mm41 10 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 10 months ago
I`m bullish
πŸ‘οΈ0
mm41 mm41 10 months ago
The cheapest blue-chip stock . buy for a good long term
πŸ‘οΈ0
debunker1 debunker1 7 years ago
Novartis' Entresto is nothing more than an attempt to extend the patent life of Diovan (Valsartan). There is nothing to prove that Entresto is any better than the now generically available Valsartan.
πŸ‘οΈ0
trendmkr trendmkr 9 years ago
A Look at the Science Behind Bayer’s Latest Buy

http://marketexclusive.com/a-look-at-the-science-behind-bayers-latest-buy/1194/
πŸ‘οΈ0
MasterofCoin15 MasterofCoin15 10 years ago
this stock don't play... up 50% since last year..
πŸ‘οΈ0
dragonball dragonball 15 years ago
how come this board is dead?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Yes, hope so eom
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
well it must be good if it made it to phase 3
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
maybe its a cancer drug? dont know oncological maybe. ?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
very true. I will be picking up 100 shares and just letting it ride you think it might dip a bit?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
no,if Management has time to talk to me, they are not busy enough. I will let them be the PPS is good imo

πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
what exactly does nexevar do?
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
seriously though this looks like a pretty good company have you spoken to management?
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
then you are about to move on up, to the east side to a deluxe apartment in the sky when you take this new brand of bayer pill lol
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
yes i do

πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Knowing your alias you take the dollar store brand lol

j/k
πŸ‘οΈ0
JT_Marlin JT_Marlin 19 years ago
Is this bayer like the one in my medicine cabinet
πŸ‘οΈ0
smpathy4dadevil smpathy4dadevil 19 years ago
Bayer And Onyx Say 39% Progress On Phase III Nexavar Trial In Patients With Advanced Kidney Cancer - Quick Facts [BAY]

11/3/2005 4:19:02 AM Bayer Pharmaceuticals Corp. (BAY) and Onyx Pharmaceuticals, Inc. (ONXX) provided an update on the Nexavar Tablets Phase III trial in patients with advanced renal cell carcinoma or kidney cancer.

Based on announced interim analysis, there was an estimated 39% improvement in survival for patients receiving Nexavar versus those receiving placebo.

The final survival analysis, which is planned when 540 events have occurred, is not expected for some time. Therefore, while the findings of the interim analysis did not reach statistical significance, these early results suggest a favorable survival trend for patients who received Nexavar.

http://realtimetraders.com/sp/breakingnews.asp?vid=9625264



πŸ‘οΈ0